CANADA; INDIA —Canada's domestic nuclear medicine manufacturing sector is set for a major expansion as Jubilant Draximage, a subsidiary of India-based Jubilant Pharmova, commits CAD 94.5 million to upgrade and scale its facility in Kirkland, Quebec. The project, backed by CAD 23.8 million from the Canadian federal government's Strategic Response Fund, focuses primarily on doubling output for RUBY-FILL, a flagship generator producing Rubidium-82 used in cardiac positron emission tomography (PET) scans.
The strategic investment responds to rapid market adoption, with the user base for the targeted cardiac diagnostic technology doubling over the past three years. Operating as the sole Canadian facility producing these specialized radiopharmaceutical categories, the expanded plant will strengthen supply chain resilience for essential diagnostic tools across global healthcare networks. Jubilant Pharmova operates globally across radiopharmaceuticals, allergy immunotherapy, and contract manufacturing, employing roughly 5,500 people worldwide.
This initiative reflects a broader shift toward securing critical medical infrastructure and advancing precision medicine capabilities, particularly in cardiology, oncology, and neurology. By modernizing production lines and expanding capacity, the investment mitigates supply disruption risks for radioisotopes and targeted imaging agents. These diagnostic solutions allow medical professionals to perform non-invasive assessments of coronary artery disease, facilitating early intervention and tailored therapeutic care.
For institutional investors and healthcare providers, the expansion highlights rising demand for specialized radiopharmaceuticals and high-value life science manufacturing. Government co-investment underscores public sector commitment to boosting domestic bio-manufacturing capabilities and high-skilled employment. The increased operational capacity positions the company to capture additional market share across North America and international nuclear medicine sectors while ensuring consistent supply for healthcare providers.
